ATS 2019 Virtual Final Program

215 “Not Until I Have To”: Care Seeking and Delay of Care During COPD Exacerbations/ V.S. Fan, J.P. Young, T.L. Simpson, R. Trivedi, C.E. Simons, J.D. Edelman, E.R. Swenson, E.R. Locke, C.B. Kramer, C. Battaglia, Seattle, WA, p.A7116 216 A Feasibility Study to Examine Real-World Use of Chronic Obstructive Pulmonary Disease (COPD) Daily Digital Respiratory Symptom Collection in a Primary Care Setting/ G. Criner, T. Cole, K. Hahn, K. Kastango, J. Eudicone, I. Gilbert, Philadelphia, PA, p.A7117 217 Accuracy Comparison of a Machine Learning Readmission Prediction Model with HOSPITAL and PEARL Scores for Chronic Obstructive Pulmonary Disease (COPD) Inpatients/ M.J. Hemmrich, S. Kaskovich, L.R. Venable, K. Carey, M.M. Churpek, V.G. Press, Chicago, IL, p.A7118 218 Matching Patients with Chronic Obstructive Pulmonary Disease (COPD) to Personalized Care: A Novel Machine Learning Tool to Predict Cause of 90-Day Readmission/ S. Kaskovich, M.J. Hemmrich, L.R. Venable, K. Carey, M.M. Churpek, V.G. Press, Chicago, IL, p.A7119 219 Association of Pneumonia with Care Services, Readmission, and Death Among Veterans Hospitalized for Chronic Obstructive Pulmonary Disease/ A. Bryant, L. Spece, L.M. Donovan, T. Keller, M. Griffith, L.C. Feemster, D.H. Au, Seattle, WA, p.A7120 220 Loneliness and Emergency Department Visits in Chronic Obstructive Pulmonary Disease/ P. Marty, R. Benzo, Rochester, MN, p.A7121 221 Long-Term Benzodiazepine Use Among Patients with Chronic Obstructive Pulmonary Disease and Comorbid Posttraumatic Stress Disorder/ L.M. Donovan, C.A. Malte, L.J. Spece, M.F. Griffith, L.C. Feemster, S.B. Zeliadt, D.H. Au, E.J. Hawkins, Seattle, WA, p.A7122 222 Association Between Socioeconomic Position and Health-Related Quality of Life in Chronic Obstructive Pulmonary Disease/ G.R. Oates, I. Stepanikova, E. Baker, E.A. Regan, K.E. Lowe, N. Putcha, N.N. Hansel, D.L. DeMeo, T. Parekh, M.T. Dransfield, Birmingham, AL, p.A7123 223 Patterns of Beliefs About Comorbid Illness Among Patients with COPD Are Associated with Overall Health and Functioning/ A. Federman, K. Muellers, Y. Liu, R. O’Conor, M.S. Wolf, J.P. Wisnivesky, New York, NY, p.A7124 224 Gender and Racial Social Inequalities in Chronic Obstructive Pulmonary Disease/ T. Parekh, S. Patel, Y.-I. Kim, A. Cherrington, S. Bhatia, M.T. Dransfield, Birmingham, AL, p.A7125 225 Self-Reported Knowledge of the Harms and Benefits of Inhaled Therapies and Primary Care Prescribing Practices in COPD/ L. Spece, C. Helfrich, M. Griffith, L.M. Donovan, T. Keller, A. Bryant, L.C. Feemster, D.H. Au, Seattle, WA, p.A7126 CLINICAL POSTER DISCUSSION SESSION D103 IDIOPATHIC INTERSTITIAL PNEUMONIAS: NATURAL HISTORY AND PROGNOSIS 1:30 p.m. - 3:30 p.m. KBHCCD Room C140/C142 (Level 1) Poster Viewing 1:30-2:15 Discussion 2:15-3:30 Chairing: N. Goh, MBBS, PhD, Melbourne, Australia R.J. Shah, MD, MSCE, San Francisco, CA J.S. Lee, MD, Aurora, CO 101 Effect of MUC5b Genetic Polymorphism on Response to Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist BMS-986020 in a Phase 2 Clinical Trial in Idiopathic Pulmonary Fibrosis/ A. Minnich, M. Yang, S. Du, B. Soule, Y. Luo, Princeton, NJ, p.A7127 102 Social and Environmental Determinants of Lung Function in Patients with Idiopathic Pulmonary Fibrosis/ K.A.M. Johannson, E. Noth, H.R. Collard, B.J. Ley, N. Thakur, S.D. Nathan, Calgary, Canada, p.A7128 103 Hospital-Associated Outcomes for IPF Patients with Lung Cancer/ B. Bade, A. Shojaee, M. Gulati, New Haven, CT, p.A7129 104 The MUC5B Promoter Polymorphism and Telomere Length in Chinese Patients with Idiopathic Pulmonary Fibrosis/ H. Wang, H. Peng, Y. Zhuang, M. Cao, Y. Li, K. Zhou, J. He, G. Liang, H. Cai, J. Dai, Nanjing, China, p.A7130 105 Clinical Utility of Serum S100 Calcium Binding Protein A4 in Idiopathic Pulmonary Fibrosis/ N. Akiyama, H. Hozumi, H. Yasui, M. Kono, Y. Suzuki, M. Karayama, K. Furuhashi, N. Enomoto, T. Fujisawa, N. Inui, Y. Nakamura, T. Suda, Hamamatsu, Japan, p.A7131 106 Innate and Adaptive Immunity in Subclinical ILD in the Multi-Ethnic Study of Atherosclerosis/ A. Podolanczuk, E.J. Bernstein, J. Kim, G. Raghu, S.M. Kawut, M. Doyle, R. Tracy, R.G. Barr, N. Jenny, D.J. Lederer, New York, NY, p.A7132 107 Frailty and Longitudinal Physiologic Outcomes in Older Patients with Idiopathic Pulmonary Fibrosis/ J.S.V. Sheth, M. Xia, Y. Wang, S. Murray, C.A. Meldrum, E.A. Belloli, M.L. Salisbury, E.S. White, C.H. Holtze, B. Wang, K.R. Flaherty, Ann Arbor, MI, p.A7133 108 Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis: Visit-to-Visit Variability and the Role of 6-Minute Walk Distance to Validate Changes/ S.D. Nathan, M. Yang, E.A. Morgenthien, J.L. Stauffer, Falls Church, VA, p.A7134 109 First-in-Human Imaging of CCR2 Cell Inflammation in Idiopathic Pulmonary Fibrosis/ S.L. Brody, J.J. Atkinson, S.P. Gunsten, D.H. Sultan, H.P. Luehmann, J. Pan, G.S. Heo, R. Laforest, S. Schwarz, M. Hoelscher, D.E. Byers, A. Shifren, T. Russell, D.L. Chen, Y. Liu, St. Louis, MO, p.A7135 ATS 2019 • Dallas, TX WEDNESDAY • MAY 22 383 WEDNESDAY AFTERNOON